These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11311192)

  • 1. A means to an end: an overview of a hyperlipidemia outcomes management program.
    Patel B; Perez HE
    Am J Med; 2001 Apr; 110 Suppl 6A():12S-16S. PubMed ID: 11311192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering interventions in managed care settings.
    Fox J; Jones K
    Am J Med; 2001 Apr; 110 Suppl 6A():24S-30S. PubMed ID: 11311194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans.
    Latts LM
    Am J Med; 2001 Apr; 110 Suppl 6A():17S-23S. PubMed ID: 11311193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ; Hunninghake DB;
    J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic benefits of aggressive lipid lowering: a managed care perspective.
    McKenney JM; Kinosian B
    Am J Manag Care; 1998 Jan; 4(1):65-74. PubMed ID: 10179907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goal attainment in patients referred to a telephone-based dyslipidemia program.
    Palmieri J; Redline S; Morita R
    Am J Health Syst Pharm; 2005 Aug; 62(15):1586-91. PubMed ID: 16030368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A literature review of cardiovascular disease management programs in managed care populations.
    Ara S
    J Manag Care Pharm; 2004; 10(4):326-44. PubMed ID: 15298531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the relationship between a chronic disease care management program and california pay-for-performance diabetes care cholesterol measures in one medical group.
    Cutler TW; Palmieri J; Khalsa M; Stebbins M
    J Manag Care Pharm; 2007 Sep; 13(7):578-88. PubMed ID: 17874864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving cholesterol target in a managed care organization (ACTION) trial.
    Straka RJ; Taheri R; Cooper SL; Smith JC
    Pharmacotherapy; 2005 Mar; 25(3):360-71. PubMed ID: 15843283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging the quality gap in diabetic hyperlipidemia: a practice-based intervention.
    Mehler PS; Krantz MJ; Lundgren RA; Estacio RO; MacKenzie TD; Petralia L; Hiatt WR
    Am J Med; 2005 Dec; 118(12):1414. PubMed ID: 16378790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Balbisi EA
    Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical context: current concepts of coronary heart disease management.
    Jacobson TA
    Am J Med; 2001 Apr; 110 Suppl 6A():3S-11S. PubMed ID: 11311191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipids in women: screening and treatment.
    Walsh JM
    J Am Med Womens Assoc (1972); 2003; 58(4):240-7. PubMed ID: 14640255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of an informatics-based intervention to increase statin prescription for secondary prevention of coronary disease.
    Lester WT; Grant RW; Barnett GO; Chueh HC
    J Gen Intern Med; 2006 Jan; 21(1):22-9. PubMed ID: 16423119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices.
    Walsh MN; Simpson RJ; Wan GJ; Weiss TW; Alexander CM; Markson LE; Berger ML; Pearson TA
    Am J Manag Care; 2002 Nov; 8(11):937-46. PubMed ID: 12437309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience).
    Merenich JA; Lousberg TR; Brennan SH; Calonge NB
    Am J Cardiol; 2000 Feb; 85(3A):36A-42A. PubMed ID: 10695706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.